ClinicalTrials.gg
CompletedNCT02142959Updated Jun 3, 2025Results posted

RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE

A Phase 2 interventional study of Omaveloxolone Lotion 0.5% and Omaveloxolone Lotion 3% in Breast Cancer, sponsored by Biogen. Completed at 27 sites in United States. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-03.

Sponsored by Biogen · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
187
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Study summary

Radiation dermatitis is experienced by almost all patients (up to 95%) receiving radiation therapy for cancer. Radiation dermatitis can be a serious condition because, in addition to its direct physical complications and the resulting impact on overall quality of life, it can also be a dose-limiting toxicity requiring changes to the prescribed course of radiation therapy. The most common strategy employed in an attempt to prevent or minimize radiation dermatitis involves moisturization of the irradiated area, use of a mild soap to keep the area clean, and minimizing exposure to potential mechanical irritants, such as scratching and rough clothing. However, this strategy has been shown to lack clinically significant efficacy. Consequently, there is a clinical need for new treatments that are effective in protecting against radiotherapy-induced oxidative stress and the subsequent development of radiation dermatitis.

Based on data from previous studies in animals and humans, Reata believes that omaveloxolone (RTA 408) Lotion may effectively prevent and mitigate radiation dermatitis in oncology patients undergoing radiation therapy.

This randomized, double-blind, vehicle-controlled, parallel-group trial will study the efficacy, tolerability and safety of two concentrations of omaveloxolone (RTA 408) Lotion (3% and 0.5%) versus vehicle in patients with breast cancer for whom radiation therapy is recommended.

02

Conditions studied

  • Breast Cancer

Keywords

  • RTA 408
  • RTA 408 Lotion
  • Breast cancer
  • Radiation therapy
  • Radiation dermatitis
  • Oxidative stress
  • Inflammation
  • omaveloxolone
03

In context

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's enrollment of 187 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.

Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult female patients (18 to 75 years of age, inclusive);
  2. Patients diagnosed with ductal carcinoma in situ or non-inflammatory breast adenocarcinoma who have been referred for post-operative radiotherapy and have had no prior radiation treatment to that breast;
  3. Patients planning to undergo 3D conformal radiation therapy to the whole breast (as part of breast-conservation therapy / lumpectomy) or chest wall (as part of post-mastectomy irradiation), with or without treatment of regional lymph nodes (i.e., axillary, supraclavicular, or internal mammary), using one of the following treatment schedules:

    1. 45 - 50.4 Gy in 1.8 Gy per day, in addition to 10-16 Gy boost
    2. 46 - 50 Gy in 2 Gy per day, in addition to 10-16 Gy boost;
  4. Patients who received breast-conservation therapy / lumpectomy must be receiving ≥ 107% of the total radiation dose (calculated from the total radiation dose including boost) to any portion of the breast, based on radiation inhomogeneity, and/or have a breast volume ≥ 1200 cc;

Exclusion criteria

Exclusion Criteria:

  1. Patients with Stage T4 or Stage IV breast cancer;
  2. Patients with prior radiation therapy to the breast treated in this study;
  3. Patients with type V or VI skin according to the Fitzpatrick scale;
  4. Patients with bilateral breast cancer;
  5. Patients receiving partial breast irradiation therapy;
  6. Patients with uncontrolled diabetes ( > 11.0%, historical values within 6 months of screening are acceptable);
  7. Patients with collagen vascular disease or vasculitis;
  8. Patients with concurrent active other than adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix;
  9. Patients with active bacterial, fungal or viral skin infections;
  10. Patients with known active or infection;
  11. Patients who intend to use any other topical cream, lotion or preparation applied to the radiation treatment area;
  12. Patients receiving concomitant chemotherapy during the course of the planned radiation treatment regimen. Patients are eligible if they are receiving sequential, or adjuvant chemotherapy that is not anticipated to be delivered during the time course of the radiation treatment regimen.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
187 participants (actual)

Study arms

  • Experimental
    omaveloxolone (RTA 408) Lotion 0.5%

    Omaveloxolone Lotion at a fixed dose of 0.5% administered topically to the radiation area, twice daily for approximately 9 weeks (up to a maximum of 16 weeks)

    Drug: Omaveloxolone Lotion 0.5% · Radiation: 3D conformal radiation therapy

  • Experimental
    omaveloxolone (RTA 408) Lotion 3%

    Omaveloxolone Lotion at a fixed dose of 3% administered topically to the radiation area, twice daily for approximately 9 weeks (up to a maximum of 19 weeks)

    Drug: Omaveloxolone Lotion 3% · Radiation: 3D conformal radiation therapy

  • Placebo comparator
    Vehicle Lotion

    Vehicle Lotion administered topically to the radiation area, twice daily for approximately 9 weeks (up to a maximum of 16 weeks)

    Drug: Vehicle Lotion · Radiation: 3D conformal radiation therapy

Interventions

  • DrugOmaveloxolone Lotion 0.5%

    Omaveloxolone lotion 0.5% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy

    Also known as: RTA 408 Lotion 0.5%

  • DrugOmaveloxolone Lotion 3%

    Omaveloxolone lotion 3% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy

    Also known as: RTA 408 Lotion 3%

  • DrugVehicle Lotion

    Lotion vehicle manufactured to mimic RTA 408 lotion will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy

  • Radiation3D conformal radiation therapy

    45 50.4 Gy in 1.8 Gy per day, in addition to 10 - 16 Gy boost or 46 - 50 Gy in 2 Gy per day, in addition to 10 - 16 Gy boost, at the physician's discretion

06

What researchers measure

Primary outcomes

  1. Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy to the Breast Following Topical Application of Omaveloxolone Lotion or Lotion Vehicle

    CTCAE Radiation dermatitis scoring: Grade 0 = No radiation dermatitis; Grade 1 = Faint erythema or dry desquamation; Grade 2 = Moderate to brisk erythema, patchy moist desquamation, mostly confined to skin folds and creases, moderate edema; Grade 3 = Moist desquamation in areas other than skin folds and creases, bleeding induced by minor trauma or abrasion; Grade 4 = Life-threatening consequences, skin necrosis or ulceration of full thickness dermis, spontaneous bleeding from involved site, skin graft indicated; Grade 5 = Death

    Time frame: Day 1 of radiation treatment through the last day of radiation treatment (maximum of 19 weeks), time averaged effect on radiation dermatitis reported

07

Results

Posted May 6, 2023

Participant flow

Participant flow — Overall Study
MilestoneOmaveloxolone (RTA 408) Lotion 0.5%Omaveloxolone (RTA 408) Lotion 3%Vehicle Lotion
Started646261
Completed595955
Not completed536
Withdrew: Adverse event100
Withdrew: Death010
Withdrew: Withdrawal by subject313
Withdrew: Administrative reasons101
Withdrew: Missing010
Withdrew: Treatment changed from radiation treatment to chemo001
Withdrew: Patient didn't complete end of study visit001

Outcome measures

PrimaryTime-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy to the Breast Following Topical Application of Omaveloxolone Lotion or Lotion Vehicle

CTCAE Radiation dermatitis scoring: Grade 0 = No radiation dermatitis; Grade 1 = Faint erythema or dry desquamation; Grade 2 = Moderate to brisk erythema, patchy moist desquamation, mostly confined to skin folds and creases, moderate edema; Grade 3 = Moist desquamation in areas other than skin folds and creases, bleeding induced by minor trauma or abrasion; Grade 4 = Life-threatening consequences, skin necrosis or ulceration of full thickness dermis, spontaneous bleeding from involved site, skin graft indicated; Grade 5 = Death

Time frame:
Day 1 of radiation treatment through the last day of radiation treatment (maximum of 19 weeks), time averaged effect on radiation dermatitis reported
Reported as:
Least squares mean · Grade
Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy to the Breast Following Topical Application of Omaveloxolone Lotion or Lotion Vehicle
GradeOmaveloxolone (RTA 408) Lotion 0.5%Omaveloxolone (RTA 408) Lotion 3%Vehicle Lotion
Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy to the Breast Following Topical Application of Omaveloxolone Lotion or Lotion Vehicle1.1 (1.0 to 1.2)1.2 (1.1 to 1.3)1.2 (1.1 to 1.3)
Statistical analysis
  • Omaveloxolone (RTA 408) Lotion 0.5% vs Omaveloxolone (RTA 408) Lotion 3% vs Vehicle Lotion · Mixed Models Analysis · p = 0.237 (Omaveloxolone treatment arms were compared with Vehicle Lotion using a hierarchical testing strategy to control the overall type I error.) · Ls mean difference final values: -0.1 · 65% CI -0.2 to 0.0Fixed factors: treatment grp \& wk of visit; covariates of site, smoking status \& surgery. Missing data imputed using each patient's worst-observation.
  • Omaveloxolone (RTA 408) Lotion 0.5% vs Vehicle Lotion · Mixed Models Analysis · p = >0.05 (Omaveloxolone treatment arms were compared with Vehicle Lotion using a hierarchical testing strategy to control the overall type I error.) · Ls mean difference final values: -0.1 · 95% CI -0.2 to 0.0Fixed factor: treatment grp \& visit wk; Covariates: site, smoking status \& breast surgery. Missing data imputed using each patient's worst-observation
  • Omaveloxolone (RTA 408) Lotion 3% vs Vehicle Lotion · Mixed Models Analysis · p = >0.05 · Ls mean difference final values: 0 · 95% CI -0.1 to 0.1Fixed factor: treatment grp \& visit wk; Covariates: site, smoking status \& breast surgery. Missing data imputed using each patient's worst-observation

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Omaveloxolone (RTA 408) Lotion 0.5%0/64 (0%)4/64 (6.3%)49/64 (76.6%)
Omaveloxolone (RTA 408) Lotion 3%1/62 (1.6%)3/62 (4.8%)54/62 (87.1%)
Vehicle Lotion0/61 (0%)0/61 (0%)50/61 (82%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventOmaveloxolone (RTA 408) Lotion 0.5%Omaveloxolone (RTA 408) Lotion 3%Vehicle Lotion
Non-cardiac chest painGeneral disorders0/641/620/61
Carbon monoxide poisoningInjury, poisoning and procedural complications0/641/620/61
InjuryInjury, poisoning and procedural complications0/641/620/61
Cardiac failure congestiveCardiac disorders1/640/620/61
CardiomyopathyCardiac disorders1/640/620/61
Incision site cellulitisInfections and infestations1/640/620/61
Alanine aminotransferase increasedInvestigations1/640/620/61
DehydrationMetabolism and nutrition disorders1/640/620/61
HypomagnesaemiaMetabolism and nutrition disorders1/640/620/61
AnxietyPsychiatric disorders1/640/620/61
Most frequent other events
Showing 10 of 44
Most frequent other events
EventOmaveloxolone (RTA 408) Lotion 0.5%Omaveloxolone (RTA 408) Lotion 3%Vehicle Lotion
FatigueGeneral disorders27/6427/6226/61
Breast painReproductive system and breast disorders20/6419/6218/61
PruritusSkin and subcutaneous tissue disorders20/6417/6212/61
Skin hyperpigmentationSkin and subcutaneous tissue disorders19/6415/6218/61
CoughRespiratory, thoracic and mediastinal disorders4/643/626/61
NauseaGastrointestinal disorders5/643/625/61
Pain in extremityMusculoskeletal and connective tissue disorders5/643/622/61
HeadacheNervous system disorders3/642/624/61
Hot flushVascular disorders3/644/624/61
Upper respiratory tract infectionInfections and infestations4/641/622/61

Baseline characteristics

Intent-to-treat population (all randomized patients whether or not they received study drug)

Age, Continuous
Age, Continuous(years)Omaveloxolone (RTA 408) Lotion 0.5%Omaveloxolone (RTA 408) Lotion 3%Vehicle LotionTotal
Mean57.7 ± 8.856 ± 10.256.6 ± 10.356.8 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Omaveloxolone (RTA 408) Lotion 0.5%Omaveloxolone (RTA 408) Lotion 3%Vehicle LotionTotal
Female646261187
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Omaveloxolone (RTA 408) Lotion 0.5%Omaveloxolone (RTA 408) Lotion 3%Vehicle LotionTotal
Hispanic or Latino24511
Not Hispanic or Latino615856175
Unknown or Not Reported1001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Omaveloxolone (RTA 408) Lotion 0.5%Omaveloxolone (RTA 408) Lotion 3%Vehicle LotionTotal
American Indian or Alaska Native0022
Asian0000
Native Hawaiian or Other Pacific Islander0011
Black or African American136524
White505451155
More than one race0000
Unknown or Not Reported1225
Region of Enrollment
Region of Enrollment(participants)Omaveloxolone (RTA 408) Lotion 0.5%Omaveloxolone (RTA 408) Lotion 3%Vehicle LotionTotal
United States646261187
08

Study locations

27 sites
  • Ironwood Cancer and Research Centers
    Mesa, Arizona 85206, United States
  • St. Joseph's Hospital and Medical Center
    Phoenix, Arizona 85013, United States
  • Arizona Cancer Center
    Scottsdale, Arizona 85258, United States
  • University of Colorado Hospital, Dept. of Radiation Oncology
    Aurora, Colorado 80045, United States
  • Norwalk Hospital
    Norwalk, Connecticut 06856, United States
  • Lakeland Regional Cancer Center
    Lakeland, Florida 33805, United States
  • John B. Amos Cancer Center
    Columbus, Georgia 31904, United States
  • St. Vincent Anderson Regional Hospital Cancer Center
    Anderson, Indiana 46016, United States
  • Parkview Research Center
    Fort Wayne, Indiana 46845, United States
  • Radiation Oncology Associates - Parkview Research Center
    Fort Wayne, Indiana 46845, United States
  • Northern Indiana Cancer Research Consortium
    South Bend, Indiana 46628, United States
  • Willis-Knighton Cancer Center
    Shreveport, Louisiana 71103, United States
  • University of Nebraska Medical Center - Eppley Cancer Center
    Omaha, Nebraska 68198, United States
  • CaroMont Health Comprehensive Cancer Center
    Gastonia, North Carolina 28054, United States
  • Sanford Health
    Bismarck, North Dakota 58501, United States
  • St. John Health System
    Tulsa, Oklahoma 74104, United States
  • Abington Memorial Hospital
    Abington, Pennsylvania 19001, United States
  • Hughes Cancer Center
    East Stroudsburg, Pennsylvania 18301, United States
  • Mount Nittany Medical Center
    State College, Pennsylvania 16803, United States
  • AnMed Health Cancer Center
    Anderson, South Carolina 29621, United States
  • 21st Century Oncology - Carolina Regional Cancer Center
    Myrtle Beach, South Carolina 29577, United States
  • Spartanburg Regional Medical Center - Gibbs Cancer Center
    Spartanburg, South Carolina 29303, United States
  • Sanford Research/USD
    Sioux Falls, South Dakota 57104, United States
  • University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229, United States
  • Cancer Care Northwest
    Spokane, Washington 99202, United States
  • Mayo Clinic - LaCrosse
    La Crosse, Wisconsin 54601, United States
  • Columbia St. Mary's
    Milwaukee, Wisconsin 53211, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Apr 2015, 10 months.

Results were first posted in May 2023, 8 years after primary completion. A results delay was requested in Jun 2015.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 10 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2014
First posted
May 20, 2014
StartActual
Jun 30, 2014
Primary completionActual
Apr 30, 2015
CompletionActual
Apr 30, 2015
Results delay requested
Jun 23, 2015
Results first posted
May 6, 2023
Last update
Jun 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02142959
Lead sponsor
Biogen
Collaborators
AbbVie
Responsible party
Sponsor
First posted
May 20, 2014
Start date
Jun 30, 2014
Primary completion
Apr 30, 2015
Completion
Apr 30, 2015
Results posted
May 6, 2023
Last update
Jun 3, 2025

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion